# ![@GIMedOnc Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1324507882172248065.png) @GIMedOnc Nicholas Hornstein

Nicholas Hornstein posts on X about in the, future, up to, just a the most. They currently have [-----] followers and [---] posts still getting attention that total [------] engagements in the last [--] hours.

### Engagements: [------] [#](/creator/twitter::1324507882172248065/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1324507882172248065/c:line/m:interactions.svg)

- [--] Week [------] +989%
- [--] Month [------] -67%
- [--] Months [-------] -16%
- [--] Year [---------] +186%

### Mentions: [--] [#](/creator/twitter::1324507882172248065/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1324507882172248065/c:line/m:posts_active.svg)

- [--] Week [--] +33%
- [--] Month [--] +6.90%
- [--] Months [--] +35%
- [--] Year [---] +272%

### Followers: [-----] [#](/creator/twitter::1324507882172248065/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1324507882172248065/c:line/m:followers.svg)

- [--] Week [-----] +0.84%
- [--] Month [-----] +4.80%
- [--] Months [-----] +59%
- [--] Year [-----] +246%

### CreatorRank: [-------] [#](/creator/twitter::1324507882172248065/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1324507882172248065/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[currencies](/list/currencies)  20% [countries](/list/countries)  3% [travel destinations](/list/travel-destinations)  3% [technology brands](/list/technology-brands)  2% [finance](/list/finance)  2% [social networks](/list/social-networks)  1% [cryptocurrencies](/list/cryptocurrencies)  1%

**Social topic influence**
[in the](/topic/in-the) 12%, [future](/topic/future) 5%, [up to](/topic/up-to) 5%, [just a](/topic/just-a) 4%, [health](/topic/health) 4%, [status](/topic/status) 4%, [the first](/topic/the-first) 4%, [met](/topic/met) 4%, [dual](/topic/dual) 4%, [atomic](/topic/atomic) 4%

**Top accounts mentioned or mentioned by**
[@oncoalert](/creator/undefined) [@thegutonclab](/creator/undefined) [@ugrewalmd](/creator/undefined) [@asco](/creator/undefined) [@oncbrothers](/creator/undefined) [@realbowtiedoc](/creator/undefined) [@larvol](/creator/undefined) [@yekeduzemre](/creator/undefined) [@suyogcancer](/creator/undefined) [@drbakaloudimd](/creator/undefined) [@andreaanampag](/creator/undefined) [@reginabarcar](/creator/undefined) [@cwspeers](/creator/undefined) [@funchainmd](/creator/undefined) [@mknollmd](/creator/undefined) [@bavilima](/creator/undefined) [@krishanjethwa](/creator/undefined) [@cancerassassin1](/creator/undefined) [@reneesaliby](/creator/undefined) [@mikeserzanmd](/creator/undefined)

**Top assets mentioned**
[Frontline Ltd. (FRO)](/topic/$fro) [Exelixis Inc (EXEL)](/topic/$exel)
### Top Social Posts
Top posts by engagements in the last [--] hours

"#GI25 Is it the hardest to pronounce name of any antibody Yes. It is also probably the best new treatment for GI malignancies Also probably yes. Daraxonrasib pan-KRASi Amazing responses in second line PDAC Making the undruggable druggable. (Someone please teach me how to pronounce this.)"  
[X Link](https://x.com/anyuser/status/1883050241093403023)  2025-01-25T07:12Z [----] followers, 75.1K engagements


"#ASCO2025 📢Practice changing for Biliary Tract and Gallbladder Cancers GAIN trial Neoadjuvant chemo drastically improves outcomes in resectable BTC/GBC Phase III randomized (N=68 stopped early due to accrual) Arm A: Gem/Cis [--] surgery Gem/Cis [--] Arm B: surgery adjuvant chemo 🤯 mOS: [----] mo (A) vs. [----] mo (B) HR [----] p=0.04 ✅R0 rate: 62.5% (A) vs. 33.3% (B) 30-day mortality: 4.2% vs. 24% TRAEs (G3+): 39% (A); no G5 Perioperative chemotherapy is a major advance in patients with BTC/GC almost doubling mOS New standard of care @ASCO @OncoAlert"  
[X Link](https://x.com/GIMedOnc/status/1925724575255421388)  2025-05-23T01:24Z [----] followers, 17.2K engagements


"Interesting signal in a very tough disease 👀🧬 at #GI26 Dr. Mahalingam presented a randomized phase II testing gemcitabine/abraxane with or without elraglusib in untreated metastatic PDAC. Quick background: elraglusib is a GSK-3 inhibitor targeting a pathway implicated in tumor growth metabolism and immune regulation. 📊 The data Median OS [----] vs [---] months HR [----] in favor of the elraglusib combo ORR [----] vs [----] percent Takeaway: This is not a moonshot but its a real ground shot. In metastatic pancreatic cancer a clear OS signal in a randomized study matters. Curious to see if this moves"  
[X Link](https://x.com/GIMedOnc/status/2009799178956972456)  2026-01-10T01:27Z [----] followers, [----] engagements


"Ive seen alot of posts recently about pancreatic cancer being cured in mice. Just a general reminder of something that is currently hung in my office:"  
[X Link](https://x.com/GIMedOnc/status/2017973668232523989)  2026-02-01T14:49Z [----] followers, [----] engagements


"@UGrewalMD Did someone say CRC"  
[X Link](https://x.com/GIMedOnc/status/2019631449536884860)  2026-02-06T04:37Z [----] followers, [---] engagements


"It finally happened. A tumor-agnostic ctDNA assay came back positive. The tumor-informed assay was negative. Yes both were sent. Lets move on 😅 This is actually a useful reminder that ctDNA is not one thing. There are a variety of flavors and discordant results are exactly where those differences start to matter. Tumor-informed assays 🧬 Built from the patients own tumor 🎯 Optimized for detecting very low levels of residual disease Slower and requires tumor tissue Tumor-agnostic assays ⚡ Off-the-shelf and fast 🌍 Broader signal without needing tissue 👉 Useful when tissue isnt available or"  
[X Link](https://x.com/GIMedOnc/status/2020144182174572577)  2026-02-07T14:34Z [----] followers, [----] engagements


"@UGrewalMD 100%. We will see orthogonal technologies improve these assays. Likely the path forward for best ROC"  
[X Link](https://x.com/GIMedOnc/status/2020157559395561569)  2026-02-07T15:27Z [----] followers, [---] engagements


"@manjuggm @allisonoconn Cytoreduction in CRC should be performed with exceptionally careful patient selection"  
[X Link](https://x.com/GIMedOnc/status/2020549142666203493)  2026-02-08T17:23Z [----] followers, [---] engagements


"@Dr_R_Kurzrock Oh you mean all the negative trials that show inferior outcomes Dont mind those"  
[X Link](https://x.com/GIMedOnc/status/2020656360921448504)  2026-02-09T00:29Z [----] followers, [---] engagements


"Confession: before I was a GI oncologist I was a computer nerd. PhD in computational biology. I still get a strange amount of joy from a clean terminal window. Ive been using large language models since they first became publicly available. Early versions were rough. Hallucinations everywhere. Impressive demos but not something youd trust with real work. Over time they became genuinely useful. Great for drafting. Helpful for coding. Tools like OpenEvidence started to feel practical in day-to-day life. A clear productivity boost but still incremental. This past week felt different. Using"  
[X Link](https://x.com/GIMedOnc/status/2022129974312943720)  2026-02-13T02:05Z [----] followers, 11.6K engagements


"@danielkimjung @mattshumer_ Mostly using Claude Code but both work very well. Send me a DM and happy to chat"  
[X Link](https://x.com/GIMedOnc/status/2022303328487510078)  2026-02-13T13:34Z [----] followers, [--] engagements


"Is it sexy No. Is it incredibly important for how we treat patients Absolutely 🧠🧬 For over [--] years [--] months of oxaliplatin plus a fluoropyrimidine has been the default for stage III colon cancer and often high-risk stage II and rectal cancer. The cost has always been cumulative neuropathy that can follow patients for life ⚡🖐 The SCOT trial the largest study in the IDEA collaboration gives us long-term clarity with nearly [----] patients and more than [--] years of follow-up: 📊 5-yr DFS identical with [--] vs [--] months: 72.9% vs 72.9% 📈 5-yr OS identical: 82.4% vs 82.4% ✅ Noninferiority for OS"  
[X Link](https://x.com/GIMedOnc/status/2010011999254536576)  2026-01-10T15:32Z [----] followers, 56.2K engagements


"@5_utr Rectal cancer begs to differ. https://www.nejm.org/doi/abs/10.1056/NEJMoa2404512 https://www.nejm.org/doi/abs/10.1056/NEJMoa2404512"  
[X Link](https://x.com/GIMedOnc/status/2010414058978345202)  2026-01-11T18:10Z [----] followers, [--] engagements


"Youre too young is not a diagnosis. Colorectal cancer is now the leading cause of cancer death for men and women under [--]. It is one of the only major cancers still increasing in incidence. This is not a future problem. This is already here. A few things that matter: Screening works. Average-risk screening starts at [--] earlier if you have risk factors. Symptoms in young people are real and should never be brushed off. New rectal bleeding constipation diarrhea bowel habit changes abdominal pain or unexplained anemia are warning signs. If symptoms are new or persistent push for evaluation. If"  
[X Link](https://x.com/GIMedOnc/status/2014766019928052192)  2026-01-23T18:23Z [----] followers, [----] engagements


"@fernandbteich This is why all CRC patients need NGS (ALASCCA a great excuse)"  
[X Link](https://x.com/GIMedOnc/status/2015082481465147672)  2026-01-24T15:21Z [----] followers, [---] engagements


"@HemeOncBuddy @VivekSubbiah @chadinabhan @PGrivasMDPhD @BrainTumorDoc @montypal @weldeiry @PavlosMsaouel It may have originated there but it was perfected in Greece"  
[X Link](https://x.com/GIMedOnc/status/2018107923797360728)  2026-02-01T23:43Z [----] followers, [--] engagements


"@IshwariaMD Why revive a study from [----] that clearly has a number of confounders and is practically imbalanced between groups (4x as many non-cannabis patients on first line therapy and liver metastasis 3x as often in the cannabis group)"  
[X Link](https://x.com/GIMedOnc/status/1692614242766094775)  2023-08-18T19:07Z [----] followers, [----] engagements


"Thought-provoking study out of the Flatiron Health real-world database. Omission of 5-FU Bolus assoc w/ decreased side-effect and no change in outcomes. Many caveats: retrospective data nuance of adjusting for "baseline clinical characteristics". https://jnccn.org/view/journals/jnccn/aop/article-10.6004-jnccn.2024.7029/article-10.6004-jnccn.2024.7029.xmlcontent=fullhtml-7350 https://jnccn.org/view/journals/jnccn/aop/article-10.6004-jnccn.2024.7029/article-10.6004-jnccn.2024.7029.xmlcontent=fullhtml-7350"  
[X Link](https://x.com/GIMedOnc/status/1832042605858722108)  2024-09-06T13:06Z [----] followers, [----] engagements


"#GI25 abstracts are out Almost [----] abstracts and presentations So much great research. Some highlights: CAR T For Solid Tumor (CRC) GCC19 CART for refractory mCRC with a response rate of 80% at dose level [--] Some responses included complete metabolic response on PET (jaw dropping). https://meetings.asco.org/abstracts-presentations/241837 https://meetings.asco.org/abstracts-presentations/241837"  
[X Link](https://x.com/GIMedOnc/status/1881873348054909212)  2025-01-22T01:15Z [----] followers, [----] engagements


"#GI25 The one and only @mgfakih on stage presenting the phase II Bot + Bol trial. [---] patients treated MSS multi-refractory mCRC Bot +/- Bal [--] vs Bot +/- Bal [---] vs SOC (lonsurf or rego) Bot + Bal smokes SoC. Some patients with prolonged responses. Safe compared to SoC. 75mg dosing to move into Ph3. Need this in the clinic ASAP"  
[X Link](https://x.com/GIMedOnc/status/1883209385444549030)  2025-01-25T17:44Z [----] followers, [----] engagements


"#GI25 Love it or hate it ctDNA is impacting clinical practice BESPOKE CRC Positive ctDNA with worse outcomes ctDNA status impacting treatment in clinical practice almost 20% of the time Is this right Too soon Regardless it is happening Need more data"  
[X Link](https://x.com/GIMedOnc/status/1883266874148016408)  2025-01-25T21:33Z [----] followers, [----] engagements


"Checkpoint inhibition in dMMR colon cancer is the future but the duration of treatment to elicit optimal response remains unknown. Dr.Diaz and Cercek of MSK put together a fantastic review and collated about a dozen trials pointing to [--] months as an optimal time point. Great weekend read https://www.nejm.org/doi/full/10.1056/NEJMc2409154 https://www.nejm.org/doi/full/10.1056/NEJMc2409154"  
[X Link](https://x.com/GIMedOnc/status/1893676815862116437)  2025-02-23T14:58Z [----] followers, 30.5K engagements


"#ASCO25 abstracts dropped CodeBreaK [---] KRAS G12C mCRC triplet approach 😮Sotorasib + Panitumumab + FOLFIRI n = [--] Treatment Refractory (Median [--] prior lines) Efficacy: ✅ORR: 57.5% DCR: 92.5% mPFS: [---] mo mOS: [----] mo Safety: Gr [--] rash/dry skin: 67.5% Neutropenia: 50% Stomatitis: 42% ❌40% discontinued FOLFIRI Small study with expected signal (but significant tox). Will be interesting as pan-KRAS come to clinic. Phase III CodeBreaK [---] exploring this in 1st-line #CRCSM #CRC @KRASKickers"  
[X Link](https://x.com/GIMedOnc/status/1925696223492587527)  2025-05-22T23:32Z [----] followers, [----] engagements


"#ASCO2025 Continuing on KRASG12C in CRC Olomorasib (second gen KRAS G12C) + Cetuximab in previously treated KRAS G12C CRC [--] patients in dose expansion [--] in optimization phase ORR 42% mPFS [---] months AEs 24% G3 1/3 of patients remain on treatment Second gen KRASG12C. fits in with similar G12C agents (CodeBreaK KANDLELIT). Time will tell how these agents fit into the clinic #CRC #OncTwitter @ASCO @OncoAlert"  
[X Link](https://x.com/GIMedOnc/status/1925721979077701779)  2025-05-23T01:14Z [----] followers, [----] engagements


"#ASCO2025 Another practice changing abstract for Gallbladder Cancer Phase [--] RCT in locally advanced gallbladder cancer not appropriate for R0 resection Neoadjuvant ChemoRT vs Chemo alone n = [---] (64 NACT [--] NACRT) 🤩OS: [----] vs [----] mo (p = 0.006) ✅EFS: [----] vs [---] mo (p = 0.006) ✅R0 resection: 51.6% vs 29.7% (p = 0.01) Conditional power: 99.96% at interim NACRT as preferred strategy in locally advanced gallbladder Wonder how this compares against perioperative chemotherapy seen in another abstract (although notably different populations)"  
[X Link](https://x.com/GIMedOnc/status/1925752165567492411)  2025-05-23T03:14Z [----] followers, [----] engagements


"#ASCO2025 Immunotherapy in MSS colorectal cancer actually working 👀 Phase [--] trial of DSP107 (CD47 x 4-1BBL) atezolizumab in 3L MSS CRC Heavily pretreated (76% liver mets) n = [--] (19 mono [--] combo) 🤩 OS not yet reached: [----] mo (combo) vs [---] mo (mono) ✅ DCR: 62% (combo) vs 26% (mono) ✅ [--] CR [---] yrs [--] PR [--] mo (86% shrinkage) 🛡 Well tolerated: mostly Grade [--] IRRs fatigue anemia A spark in cold MSS CRC 🔥 Randomized Ph2 on the way. @ASCO @larvol @oncoalert @oncbrothers 🎙 Featured Voices: @yekeduz_emre @DRBakaloudiMD @AndreaAnampaG @ReginaBarCar @cwspeers @FunchainMD @MKnoll_MD @bavilima"  
[X Link](https://x.com/GIMedOnc/status/1925912243876643022)  2025-05-23T13:50Z [----] followers, [----] engagements


"#ASCO25 Sometimes the most valuable strategies in oncology come from organ systems that have pushed the furthest. The InTRist trial explores whether moving immunotherapy before chemoradiation in bulky unresectable stage III NSCLC improves outcomes. It does. [--] patients randomized 1:1 to receive neoadjuvant toripalimab + chemotherapy prior to CRT had: 12-month PFS: 89.4% vs 57.8% Objective response rate: 77.8% vs 40% Hazard ratio for progression: [----] (p = 0.034) This builds on PACIFIC (durvalumab after CRT) but moves immunotherapy earlierpriming the immune response before local therapy."  
[X Link](https://x.com/GIMedOnc/status/1926663377004171611)  2025-05-25T15:35Z [----] followers, [----] engagements


"#ASCO25 DESTINY-Gastric04 sets a new 2L standard for HER2+ gastric/GEJ cancer. T-DXd vs Ramucirumab/Paclitaxel in post-trastuzumab GEJ/gastric AC (N=494): 🧬 OS: [----] vs [----] mo (HR [----] p=0.004) 📉 PFS: [---] vs [---] mo 🎯 ORR: 44% vs 29% Some minor concerns: ⚠ ILD/pneumonitis in 14% (mostly grade 12) Only 26% of control arm got T-DXd post-progression 🔬 HER2 heterogeneity 📊 Subgroup CI [---] in many cohorts 🌍 Open-label + regional variability Regardless this establishes T-DXd as the preferred 2L optionif HER2 remains positive. Gastric follows in the footsteps of breast where pathologic"  
[X Link](https://x.com/GIMedOnc/status/1928793138174263698)  2025-05-31T12:38Z [----] followers, [----] engagements


"#ASCO25 CAIRO-6 delivers the first phase [--] data for perioperative chemo in resectable colorectal peritoneal mets. CRS + HIPEC periop systemic therapy (N=358) 🔵 PFS: [--] vs [--] mo 🔵 DFS: [--] vs [--] mo 🔴 OS: [--] vs [--] mo (NS) 📊 3-yr OS: 54% vs 53% no meaningful difference ❌ Did not meet OS endpoint Still a signal in synchronous right-sided tumors. And [--] mo median OS remains exceptional for this setting. A win for surgical trial executionand for multidisciplinary clarity in peritoneal disease"  
[X Link](https://x.com/GIMedOnc/status/1928872918714290342)  2025-05-31T17:55Z [----] followers, [----] engagements


"#ASCO25 Found the mad the myth the legend @Larvol Love being able to see people in person and discuss the latest in oncology"  
[X Link](https://x.com/GIMedOnc/status/1929206074927620156)  2025-06-01T15:59Z [----] followers, [----] engagements


"Had a conversation with someone outside of healthcare recently who was shocked by how long it takes to run clinical trials in the U.S (not to mention expensive). I tried to explainits not just the science. Its the infrastructure. Every site needs dozens of personnel many of whom are required by regulatory frameworks thatwhile importanthavent kept pace with the speed of innovation. Startup time Often 3-6+ months before a single patient is enrolled. Meanwhile 📊 In the past [--] years China launched [--] novel oncology drugsnearly matching the U.S. (85)after trailing far behind just a decade ago."  
[X Link](https://x.com/GIMedOnc/status/1934722555673297095)  2025-06-16T21:19Z [----] followers, 28.3K engagements


"Feel like Ive felt this way before. @TheGutOncLab @UGrewalMD @Deebacca @TimothyJBrownMD"  
[X Link](https://x.com/GIMedOnc/status/1960531274021454101)  2025-08-27T02:34Z [----] followers, [----] engagements


"An aspirin a day keeps the medical oncologist away ALASCCA made waves at GI ASCO 🌊 when it showed that a cheap widely available druglow-dose aspirincan meaningfully reduce recurrence risk in a genomically selected subset of colorectal cancer. This randomized placebo-controlled trial enrolled patients with stage IIII rectal cancer or stage IIIII colon cancer harboring PI3K pathway alterations. Roughly a third of screened patients carried eligible mutations including canonical PIK3CA hotspots (exons 9/20 group A) or other moderate/high-impact PI3K pathway variants (PIK3CA PIK3R1 PTEN group B)."  
[X Link](https://x.com/GIMedOnc/status/1968501438633369847)  2025-09-18T02:24Z [----] followers, [----] engagements


"Honored to receive the NCI Gold Certificate of Excellence 🏅 Grateful to every patient who enrolls in a trial you make progress possible. And to our research teams who work behind the scenes every day 💪 Proud that I now have several IITs open @NorthwellHealth bringing new treatments to patients. @TheGutOncLab #ClinicalTrials #GIOnc #CancerResearch"  
[X Link](https://x.com/GIMedOnc/status/1978911480407019691)  2025-10-16T19:50Z [----] followers, [----] engagements


"Are you someone who treats GI cancer studies it or just loves arguing about hazard ratios Then this ones for you. @CancerNetwork Twitter takeover this Sunday (10/20) at [--] PM EST join @TimothyJBrownMD @UGrewalMD and me as we unpack the biggest #ESMO25 #GIonc trials live. @TheGutOncLab @OncoAlert @CancerNetwrk 🎙 Tune in at [--] PM EST on 10/20 to catch a live discussion on top GI abstracts from #ESMO25 🎙 @TimothyJBrownMD @GIMedOnc and @UGrewalMD will discuss all you need to know to stay up to date Join here: https://t.co/5YA6X9Xnd2 https://t.co/pU62Ybooiq 🎙 Tune in at [--] PM EST on 10/20 to catch"  
[X Link](https://x.com/GIMedOnc/status/1979299232424300758)  2025-10-17T21:31Z [----] followers, [----] engagements


"ASPEN grows but most tumors dont 🌲 Largest prospective study yet of nonfunctioning pancreatic NETs [--] cm (n = 1000) a question thats quietly divided the field for years: watch or cut 🩻 87% managed with active surveillance (AS) vs 13% with surgery (SR) 📈 Relevant tumor growth during AS: 7.5% at [--] yrs 16.7% at [--] yrs 🧬 [--] cm was the only independent predictor of slower growth (HR [----] p = 0.014) 🔪 Severe postop complications in 16% of surgical cases 🫀 Liver mets rare (0.3%) and OS identical between AS and SR (p = 0.53) Takeaway: For most small asymptomatic NF-PanNETs observation is not just"  
[X Link](https://x.com/GIMedOnc/status/1979570816971837499)  2025-10-18T15:30Z [----] followers, [----] engagements


"ctDNA guidance takes a step not a leap in stage III colon cancer 🧬🩸 DYNAMIC-III (LBA9) tested ctDNA-guided adjuvant de-escalation after surgery for stage III colon cancer. 🧪 [---] patients [---] ctDNA randomized to ctDNA-guided vs standard chemo 💉 Oxaliplatin use: 35% vs 89% (p0.001) 📈 3-year RFS: 85.3% vs 88.1% 2.8% (97.5% CI 8.0%) non-inferiority not met ⚖ Grade [--] AEs (6.2% vs 10.6%) hospitalizations (8.5% vs 13.2%) ✅ Low-risk (T13N1) subgroup: outcomes nearly identical Takeaway: ctDNA de-escalation sharply cuts oxaliplatin use and toxicity but NI wasnt formally met meaning the trial"  
[X Link](https://x.com/GIMedOnc/status/1980104266464506000)  2025-10-20T02:50Z [----] followers, 10.7K engagements


"My #OncoAlertAF TOP3 from #ESMO25 featuring a bold new format: just two. ✅ NICHE-2 ✅ STELLAR-303 Because quality quantity 😎 @OncoAlert @TheGutOncLab @UGrewalMD @TimothyJBrownMD Our #OncoAlertAF 🚨Colleague @GIMedOnc of @NorthwellHealth with his TOP picks of #GIOncology Trials Presented at #ESMO25 for the OncoAlert TOP3 Series post ESMO [----] more to come. ✅NICHE2 ✅STELLAR [---] @pashtoonkasi @CathyEngMD @marklewismd @AndresC27622123 @manjuggm https://t.co/jbspJyWHU1 Our #OncoAlertAF 🚨Colleague @GIMedOnc of @NorthwellHealth with his TOP picks of #GIOncology Trials Presented at #ESMO25 for the"  
[X Link](https://x.com/GIMedOnc/status/1984242729476637048)  2025-10-31T12:55Z [----] followers, [----] engagements


"Grateful for the lessons learned from #MCCR23 and constantly in awe of my cofellows and junior faculty from @MDAndersonNews. Until next time San Diego. @AnoutiBilal @JustinLebenthal"  
[X Link](https://x.com/anyuser/status/1685457171436466176)  2023-07-30T01:07Z [----] followers, [----] engagements


"Honored to receive a @ConquerCancerFd YIA to study how the tumor microenvironment of colorectal cancer and be modified to personalize therapy and improve outcomes. Thankful to my mentors @jpshen_md and @skopetz for the support and guidance. Congratulations to this year's class of Conquer Cancer Grant and Award recipients We can't wait to celebrate with you at #ASCO24 Full list of recipients: https://t.co/mCaRLSVLik https://t.co/g8OPMThLia Congratulations to this year's class of Conquer Cancer Grant and Award recipients We can't wait to celebrate with you at #ASCO24 Full list of recipients:"  
[X Link](https://x.com/anyuser/status/1795574208426373448)  2024-05-28T21:53Z [----] followers, [----] engagements


"A few decades later training is finally complete. A great feeling to celebrate the end of fellowship with such an amazing group of future oncologists. Honored to receive the Waun Ki Hong Award for Achievement in Basic Science Research. Thanks to all my mentors friends and family who helped me along the way"  
[X Link](https://x.com/anyuser/status/1801815406534864897)  2024-06-15T03:14Z [----] followers, [----] engagements


"Happy Fathers Day to all Afternoon Tea has successfully been cemented as a tradition (pictured last year). Formula with a drop of Earl Grey in it counts as tea right"  
[X Link](https://x.com/anyuser/status/1802426319541870956)  2024-06-16T19:41Z [----] followers, [----] engagements


"Looking forward to future long-term data from NEST studies. Neoadjuvant Bot + Bal (PD1 + CTLA4) previously with impressive results in MSIH AND MSS CRC. 71% pathologic response rate to neoadjuvant immunotherapy in MSS is outstanding Could be paradigm changing for MSS CRC. #ESMOGI24"  
[X Link](https://x.com/anyuser/status/1834206729598275868)  2024-09-12T12:25Z [----] followers, [----] engagements


"22 years ago I remember sitting in junior high biology being told I wasn't smart enough to be doctor. Today I passed the final "test" to be considered an independent Oncologist. To everyone who helped me along the way and took time to mold me thank you. To Mr. Didden guess you were wrong"  
[X Link](https://x.com/anyuser/status/1867032917249040741)  2024-12-12T02:25Z [----] followers, [----] engagements


"Time to give back to the cycle of academic life as an editor for JCO Oncology Advances. Looking forward to reading about cutting edge advances in GI Oncology"  
[X Link](https://x.com/anyuser/status/1868853729648427115)  2024-12-17T03:00Z [----] followers, [----] engagements


"#GI25 ESOPEC with that hot drop just as GI-ASCO is starting. Perioperative FLOT superior to ChemoRT for Esophageal Adenocarcinoma. Very clear results. Still wonder for some T2N0 patients if they're being overtreated with this approach. https://www.nejm.org/doi/full/10.1056/NEJMoa2409408 https://www.nejm.org/doi/full/10.1056/NEJMoa2409408"  
[X Link](https://x.com/anyuser/status/1882258996352237789)  2025-01-23T02:48Z [----] followers, [----] engagements


"#GI25 Neoadjuvant immunotherapy for MSS storms the stage. Amazing responses to Bot + Bal @Agenus_Bio Cant wait for the Phase III (or a accelerated approval; I can dream) This will be a game changer for MSS CRC. Congrats @pashtoonkasi"  
[X Link](https://x.com/anyuser/status/1883187628964725094)  2025-01-25T16:18Z [----] followers, 17.1K engagements


"#GI25 Aspirin and Celecoxib (separate studies) shown to reduce recurrence in CRC. Aspirin effect seems to be specific to PI3K mutated tumors. 🤯50% reduction with aspirin alone My clinic next week:"  
[X Link](https://x.com/anyuser/status/1883211423096164373)  2025-01-25T17:52Z [----] followers, [----] engagements


"#GI25 Trying to stay up to date with the massive amount of data in colorectal cancer Here is one slide summarizing the three major Phase III studies Generally agree with these thoughts (also shoutout to pan-KRAS aspirin Celecoxib and Bot + Bal)"  
[X Link](https://x.com/anyuser/status/1883279991640867043)  2025-01-25T22:25Z [----] followers, [----] engagements


"#GI25 As GI-ASCO comes to a close I think there are a few takeaways. [--]. Progress continues to march forward. dMMR disease is increasingly a systemically managed disease with excellent cure fraction (embrace CTLA4) [--]. IO is breaking into MSS CRC [--]. The undruggable is becoming druggable [--]. Aspirin and Celecoxib may have clinical benefit [--]. ctDNA is here to stay but we need to identify actionable strategies"  
[X Link](https://x.com/anyuser/status/1883288123091898729)  2025-01-25T22:57Z [----] followers, [----] engagements


"CheckMate 8HW is out and has ushered in a new era for dMMR mCRC. However any thoughts on using dual checkpoint inhibition for patients with advanced age or poor functional status Dual checkpoint in 90+ 80+ Start with single agent and rescue with CTLA4 if required Age is just a number but it can be informative"  
[X Link](https://x.com/anyuser/status/1884264954829721839)  2025-01-28T15:39Z [----] followers, [----] engagements


"Surprising results for colorectal cancer liver metastasis from the COLLISION trial comparing thermal ablation VS surgical resection. [---] patients in the Netherlands; patients could have up to [--] liver mets all [--] cm Interim stopping rules applied due to superior safety of ablation with comparable OS. Local control also trended towards thermal ablation Surprised local control was so similar would have expected resection to be superior. http://pubmed.ncbi.nlm.nih.gov/39848272/ http://pubmed.ncbi.nlm.nih.gov/39848272/"  
[X Link](https://x.com/anyuser/status/1896340568671945196)  2025-03-02T23:23Z [----] followers, 10.1K engagements


"Will Durvalumab + FLOT become the new standard of care in resectable gastric and GEJ adenocarcinoma Will we see results stratified by PDL1 status Will OS be mature Many questions few answers Full data to readout soon https://www.biospace.com/drug-development/astrazeneca-builds-stomach-cancer-case-for-imfinzi-with-strong-phase-iii-data https://www.biospace.com/drug-development/astrazeneca-builds-stomach-cancer-case-for-imfinzi-with-strong-phase-iii-data"  
[X Link](https://x.com/anyuser/status/1898192011657613610)  2025-03-08T02:00Z [----] followers, [----] engagements


"DYNAMIC out now with [--] year data Stage II colon cancer using ctDNA adapted strategy @NatureMedicine ❗Non-inferior statistically but should note a clinically significant difference in outcomes among T4 patients (81% vs 70% RFS and 90% vs 80% OS). Have to question those NI margins Looks great on paper but challenging to translate into clinical practice"  
[X Link](https://x.com/anyuser/status/1898520956349698550)  2025-03-08T23:47Z [----] followers, 22.2K engagements


"Aspirin can prevent colon cancer ALASCCA was a mic drop presentation at GI-ASCO earlier this year but hasn't gotten the press it deserves. Pop: [----] Resected colorectal cancer patients with PI3k mutation Intervention: 160mg Aspirin x [--] years Outcome: DFS HR .61 🤯 TTR .49 PI3k mutations occur with 35% prevalence. Are these outcomes worth performing genetic testing on all patients Or maybe all resected CRC patients should get aspirin All I know is I now have a big bottle of aspirin in my clinic. https://ascopubs.org/doi/10.1200/JCO.2025.43.4_suppl.LBA125"  
[X Link](https://x.com/anyuser/status/1911112717416714317)  2025-04-12T17:42Z [----] followers, 14.3K engagements


"#ASCO2025 abstracts are out So many great talks and studies. A few I'm really looking forward to: [--]. ATOMIC. dMMR stage III CRC addition of Atezolizumab. Finally addressing checkpoint in the adjuvant setting [--]. MATTERHORN. GC/GEJC addition of Durva to FLOT. Its a plenary. It's probably going to be a hit. [--]. LBA3502. First line mCRC. Anlotinib (TKI) versus bevacizumab added to chemotherapy. Could this redefine the mAb era [--]. AGITG Dyanmic-III. Stage III CRC study of ctDNA adapted escalation of therapy in CRC. Does ctDNA break out of its prognostic box [--]. LBL-024. Extrapulmonary NEC study of"  
[X Link](https://x.com/anyuser/status/1915212315445903427)  2025-04-24T01:12Z [----] followers, [----] engagements


"Mic-drop presentation at AACR by Cercek et al Non-operative management of MSI-H tumors showing outstanding responses to single agent IO across tumor types. [---] patients with MSI-H tumors 92% RFS at [--] years 35% of patients without ANY adverse events Option for curative intent resection not compromised. So are we ready for a new paradigm https://www.nejm.org/doi/full/10.1056/NEJMoa2404512 https://www.nejm.org/doi/full/10.1056/NEJMoa2404512"  
[X Link](https://x.com/anyuser/status/1916634381328019679)  2025-04-27T23:23Z [----] followers, 28.6K engagements


"New FDA approval for metastatic anal cancer. Retifanlimab + Carbo-Pac brings anti-PDL1 into the front-line metastatic setting. mOS [--] vs [--] months ORR 56% vs 44% Based off POD1UM-303. Great randomized study in a rare disease"  
[X Link](https://x.com/anyuser/status/1923165691387027509)  2025-05-15T23:56Z [----] followers, [----] engagements


"Congrats to @MichaelLaPelusa for a great study adding to the avalanche of data showing neoadjuvant PDL1 for MSI-H rectal cancer is safe and effective [--] year followup for pembrolizumab in MSI-H localized rectal cancer Strong use-case for ctDNA monitoring 3-year EFS 92% vs 20% based on ctDNA post-treatment 3-year EFS 80% overall Can radiation and surgery be held at bay with exceptionally strong phase II data https://www.nature.com/articles/s41467-025-59615-3 https://www.nature.com/articles/s41467-025-59615-3"  
[X Link](https://x.com/anyuser/status/1923386522566377867)  2025-05-16T14:34Z [----] followers, [----] engagements


"Two great articles by JCO in one day Article 1: MSI-H Gastric Cancer (NO LIMIT) Phase II Nivo + Ipi in the first line [--] patients 👍ORR 62% 😯CR 10% (low but perhaps not indicative of pCR) mPFS Not reached mOS Not reached Median followup of only [--] months so still needs to cook for a bit longer. Adds to the growing body of data with IO in MSI-H GI malignancies. https://ascopubs.org/doi/10.1200/JCO-24-02463 https://ascopubs.org/doi/10.1200/JCO-24-02463"  
[X Link](https://x.com/anyuser/status/1924148525966688610)  2025-05-18T17:02Z [----] followers, [----] engagements


"#ASCO2025 Not GI but maybe we can learn something for MSI-H tumors Two impressive studies in NSCLC explore whether what time you give immunotherapy matters. Spoiler: It might. 🕘 Early immuno-chemo infusions = longer survival. #LCSM @ASCO @larvol @oncoalert @oncbrothers 🎙 Featured Voices: @yekeduz_emre @DRBakaloudiMD @AndreaAnampaG @ReginaBarCar @cwspeers @FunchainMD @MKnoll_MD @bavilima @KrishanJethwa @cancerassassin1 @ReneeSaliby @MikeSerzanMD @OncBrothers @coloncancergal @ShannonWestin @SuyogCancer @supriyadocc @UGrewalMD @coffeemommy @RyanNipp @realbowtiedoc @crisbergerot"  
[X Link](https://x.com/anyuser/status/1926313047712280726)  2025-05-24T16:23Z [----] followers, [----] engagements


"Had a great time discussing #CM8HW with the @OncBrothers last week. A major step forward for our dMMR CRC patients Ipi + Nivo is now approved in dMMR/MSI-H mCRC based off #CM8HW Before #ASCO25 we had a chance to 🗣 this trial findings dosing single vs. dual ICI and AEs w/ @GIMedOnc Full 🗣: https://t.co/UK67dXqk6w Also on Oncology Brothers podcast #OncTwitter #gism #GiOnc https://t.co/JWswuTD4lr Ipi + Nivo is now approved in dMMR/MSI-H mCRC based off #CM8HW Before #ASCO25 we had a chance to 🗣 this trial findings dosing single vs. dual ICI and AEs w/ @GIMedOnc Full 🗣: https://t.co/UK67dXqk6w"  
[X Link](https://x.com/anyuser/status/1927003705909407848)  2025-05-26T14:07Z [----] followers, [----] engagements


"#ASCO2025 🚨 BREAKWATER OS data landsand it must redefine 1L standard of care in BRAF V600E-mutant mCRC. EC + mFOLFOX6 vs SOC (chemo bevacizumab): 📊 PFS: [----] vs [---] mo (HR [----] p 0.0001) 🧬 OS: [----] vs [----] mo (HR [----] p 0.0001) ✅ Dual primary endpoints met 🛡 Manageable safety profile Prior ORR data drove accelerated approval This confirms it: EC + chemo is the new SOC. Congratulations to @skopetz and team @ASCO @larvol @oncoalert 🎙 Featured Voices: @yekeduz_emre @DRBakaloudiMD @AndreaAnampaG @ReginaBarCar @cwspeers @FunchainMD @MKnoll_MD @bavilima @KrishanJethwa @cancerassassin1"  
[X Link](https://x.com/anyuser/status/1928432192801378524)  2025-05-30T12:43Z [----] followers, 12.8K engagements


"#ASCO2025 De-escalation in early rectal cancer The TAUTEM trial says maybe yes. 👀 Ph3 RCT (n=364): ChemoRT + local excision was non-inferior to TME for T2T3a/bN0 rectal cancer. DFS & OS similar. 🧬 NCCN still recommends TNT for all T3+ but not all pts may need doublet chemo or radical surgery. 2.5% OS difference so do need to consider patients carefully any insights @JohnRTMonsonMD I recall you bringing this up on tumor board last week Tailored organ-preserving strategies might be ready for prime time. #ColorectalCancer #GIonc #Deescalation #CRCSM"  
[X Link](https://x.com/anyuser/status/1928440674958893258)  2025-05-30T13:17Z [----] followers, [----] engagements


"Great talk by Dario Vignali PhD at #ASCO25 on advancing checkpoint inhibition. LAG3 is now the third checkpoint targeted clinically. But its not just about adding drugsPD-1 (Nivo) and LAG3/PD-1 (Rela/Nivo) combinations induce distinct mechanistic changes in CD8+ T cells. That means not every IO combo will behave the same. The platform you build on mattersand the optimal partner for a new immunotherapy may depend on which checkpoint backbone you start with. A compelling look at how rational combination strategies will shape the future of immuno-oncology"  
[X Link](https://x.com/anyuser/status/1928632603705323652)  2025-05-31T02:00Z [----] followers, [----] engagements


"#ASCO25 Checkpoint inhibitors rarely move the needle alone in MSS CRCbut with vilastobart (XTX101) that may be changing. 🧬 Tumor-activated Fc-enhanced anti-CTLA-4 ➕ Atezolizumab in late-line checkpoint-nave MSS CRC (N=40) 💥 In NLM patients (n=11): [--] confirmed + [--] unconfirmed PR ORR 27% 📉 All responders had marked ctDNA & CEA drops 🛡 Well-tolerated: 15% G3+ TRAEs no G5s Liver mets still tough but early efficacy + selective activation show promise in historically immune-resistant disease. #CRCSM #Immunotherapy @jgong15 @realbowtiedoc @ASCO @larvol @oncoalert"  
[X Link](https://x.com/anyuser/status/1928896033393725586)  2025-05-31T19:27Z [----] followers, [----] engagements


"Game-changer at #ASCO25 🔥 Pre-plenary press release ATOMIC is the most important adjuvant study yet for MSI-H colon cancerand its practice-changing. 🧬 Stage III dMMR colon cancer 🧪 Atezolizumab + mFOLFOX6 vs mFOLFOX6 alone 💥 3-yr DFS: 86.4% vs 76.6% ⚖ HR [----] p .0001 Across subgroups benefit was consistent. Toxicity was manageable. Immunotherapy has arrived in the adjuvant setting MSI-H colon cancer now has a new standard overnight. ❓ But do all patients still need chemo @ASCO @OncoAlert @JCO_ASCO @oncoalert @oncbrothers 🎙 Featured Voices: @yekeduz_emre @DRBakaloudiMD @AndreaAnampaG"  
[X Link](https://x.com/anyuser/status/1929170191268642826)  2025-06-01T13:36Z [----] followers, 15.3K engagements


"Great discussion for ATOMIC. Complete practice changing The paradigm for MSI-H will evolve (hopefully to nonoperative management). My thoughts The future state likely will harness tumor informed assays to predict how much IO is needed (single vs dual checkpoint) and duration of therapy Any other future predictions #ASCO25 @ASCO @larvol @oncoalert @oncbrothers 🎙 Featured Voices: @yekeduz_emre @DRBakaloudiMD @AndreaAnampaG @ReginaBarCar @cwspeers @FunchainMD @MKnoll_MD @bavilima @KrishanJethwa @cancerassassin1 @ReneeSaliby @MikeSerzanMD @OncBrothers @coloncancergal @ShannonWestin @SuyogCancer"  
[X Link](https://x.com/anyuser/status/1929248203485991378)  2025-06-01T18:46Z [----] followers, [----] engagements


"If this were a pill wed call it revolutionary. It would headline plenaries get FDA priority review and cost $10000 a month. Insteadits structured exercise. NEJM June [----] CHALLENGE Trial Stage IIIII colon cancer patients post-chemo (n=889) 📦 RCT of [--] years of supervised aerobic activity vs health education 🕒 Median follow-up: [---] years Primary Endpoint: Disease-Free Survival ✅ HR [----] (95% CI: 0.550.94) p=0.02 ➡ 5-yr DFS: 80.3% vs 73.9% Overall Survival ✅ HR [----] (95% CI: 0.430.94) ➡ 8-yr OS: 90.3% vs 83.2% Other takeaways: 🔻 Lower liver recurrence (3.6% vs 6.5%) 🔻 Fewer new primaries"  
[X Link](https://x.com/anyuser/status/1929299850400796957)  2025-06-01T22:11Z [----] followers, 13K engagements


"#ASCO25 What does [--] MET-hrs/week actually look like and how can we break it down for patients That was the CHALLENGE trial target and it delivered a DFS HR of [----]. But this isnt just a number. Its a prescription. 💡 [--] MET = resting energy [--] MET-hrs/week = [------] min of moderate activity/week Thats [----] min/day 5x/week of: 🚶♂ Brisk walking 🚴♀ Light cycling 🏃 Moderate jogging 🧘♂ Active yoga or even dancing ✅ Start small then build consistency ✅ Track itstep counters smartwatches weekly logs ✅ Frame it like any adjuvant therapy: evidence-based measurable and essential @ASCO @larvol"  
[X Link](https://x.com/anyuser/status/1929389061309133284)  2025-06-02T04:06Z [----] followers, 10.8K engagements


"Excited to share that our project LUCID (Leveraging Unstructured Clinical Information for Discovery) was selected for the @NorthwellHealth Cancer Institute Pilot Award for Mentoring in Cancer Research Im looking forward to deepening my collaboration with my mentee Ashish Samaddar an all-star internal medicine resident as we explore how much we can learn from the vast clinical data trapped in unstructured EHR data. Were applying NLP LLMs and machine learning to surface insights that could transform the delivery of cancer care. If youre a data scientist interested in joining this work were"  
[X Link](https://x.com/anyuser/status/1931432918175347166)  2025-06-07T19:27Z [----] followers, [----] engagements


"Really excited to join the OncoAlert AF Hope to keep spreading the word about clinical trials (good and bad) new innovations in oncology and ways that we can help improve care for our patients For Colleagues.By Colleagues Welcome to the #OncoAlertAF 🚨 @MarioBalsaMD @DrMirallas @GIMedOnc We Are All OncoAlert🌐 #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Abdallah81MD @FernandoOnco @ElisaAgostinett https://t.co/AWf9aghtng For Colleagues.By Colleagues Welcome to the #OncoAlertAF 🚨 @MarioBalsaMD @DrMirallas @GIMedOnc We Are All OncoAlert🌐"  
[X Link](https://x.com/anyuser/status/1932503263259115600)  2025-06-10T18:20Z [----] followers, [----] engagements


"Liver-Directed Therapies in Colorectal Cancer: Old Hats and New Tricks For patients with colorectal liver metastases resection remains the only treatment with curative potentialbut most are not candidates for up-front surgery. This review covers the evolving landscape for colorectal liver metastases 📦 Hepatic artery infusion 📦 Image-guided ablation 📦 Y90 radioembolization 📦 SBRT 📦 Liver transplantation 📈 HAI + chemo can palliate convert patients to resectable (and potentially prevent recurrence) 🔁 Transplant for uCRLM is rapidly moving from experimental to feasible in select"  
[X Link](https://x.com/anyuser/status/1933274516643516767)  2025-06-12T21:25Z [----] followers, [----] engagements


"📢 Press release dropinterpret with appropriate caution. Exelixis reports that zanzalintinib + atezolizumab improved overall survival vs regorafenib in the Phase [--] STELLAR-303 trial for third-line MSS metastatic colorectal cancer. This isnt the highest barsurvival in this setting is measured in months not yearsbut the unmet need is enormous. Finding active combinations in MSS CRC remains one of the fields toughest challenges. Immunotherapy-based regimens are the future. We just havent cracked the code for MSS disease yet. Looking forward to seeing the full data. Congratulations to"  
[X Link](https://x.com/anyuser/status/1937510913323438570)  2025-06-24T13:59Z [----] followers, [----] engagements


"🚨 Practice-Changing Data in HER2+ Gastric Cancer (May [--] Publication but now with a video) In the phase [--] DESTINY-Gastric04 trial trastuzumab deruxtecan (T-DXd) significantly improved overall survival vs ramucirumab + paclitaxel in the 2nd-line setting for patients with HER2+ metastatic gastric or GEJ adenocarcinoma. 🔹 OS: [----] vs [----] months (HR [----] P=0.004) 🔹 PFS: HR [----] 🔹 ORR: 44.3% vs 29.1% Grade [--] adverse events were common in both arms (T-DXd: 50% Ram+P: 54.1%) with interstitial lung disease (ILD)/pneumonitis seen in 13.9% of T-DXd patientsmostly low grade. 📌 This marks a new era"  
[X Link](https://x.com/anyuser/status/1938212521946525789)  2025-06-26T12:27Z [----] followers, [----] engagements


"🚨I'm hiring at Northwell🚨 If youor someone you knowhas a passion for using data to drive progress in cancer care this is a great opportunity. Were looking for a Data Scientist with expertise in NLP and machine learning to join our team at the Northwell Health Cancer Institute in collaboration with our Research Intelligence group. This is a joint appointment between oncology and data scienceworking side-by-side with clinical researchers biostatisticians and oncologists (me it's mostly me) to turn real-world data into actionable insights. What youll do: Apply NLP + ML to EHRs imaging and"  
[X Link](https://x.com/anyuser/status/1940558780690747509)  2025-07-02T23:50Z [----] followers, [----] engagements


"ATOMIC and CHALLENGE were two practice changing studies from #ASCO25 How we incorporate them into daily practice is critical. @OncoAlert @TheGutOncLab Nicholas James Hornstein MD discussed the ATOMIC and CHALLENGE Trials in a post-@ASCO interview. #gicsm @GIMedOnc https://t.co/dhi06UHVoS Nicholas James Hornstein MD discussed the ATOMIC and CHALLENGE Trials in a post-@ASCO interview. #gicsm @GIMedOnc https://t.co/dhi06UHVoS"  
[X Link](https://x.com/anyuser/status/1940577865042674036)  2025-07-03T01:06Z [----] followers, [----] engagements


"It was my thirteenth straight day of work. A Saturday on callroutine in the way hospital days often are. I stepped outside for a quick lunch finally out of scrubs and in a T-shirt and jeans hoping to feel just a little removed from it all. I sat on a bench just beyond the hospital entrance. Next to me a family was finishing a call. I overheard a few wordsbleeding scope soft pressures. Medical language spoken with uncertainty. They hung up looking overwhelmed. After a quiet moment I gently asked Is someone you love in the hospital In ten minutes they told me everythingtheir fears their hopes"  
[X Link](https://x.com/anyuser/status/1941750676410843278)  2025-07-06T06:46Z [----] followers, [----] engagements


"Headlines rarely tell the whole story. When pembrolizumab was first approved in advanced gastric and GEJ cancer the approvals seemed broad: combinations with chemo HER2-targeted therapy first-line later-line PD-L1 status didnt seem to matter. But as more data emerged the story changed. By late [----] the FDA revised these approvals: 🔹 HER2+ disease: pembrolizumab + trastuzumab + chemo now limited to CPS [--] 🧬 HER2- gastric / GEJ / esophageal: PD-L1 positivity now explicitly required 🚫 CPS [--] No benefit. Now look at MATTERHORN (durvalumab + periop FLOT). The headlines said positive trial benefit"  
[X Link](https://x.com/anyuser/status/1945663765430579424)  2025-07-17T01:56Z [----] followers, [----] engagements


"💥New paper out We reanalyzed raw sequencing data from [-----] standard-of-care Guardant360 ctDNA assays in advanced #colorectalcancer using a partner-agnostic fusion caller. 🧬 Fusions in 1.3% of patients 🧪 93% were subclonal enriched after EGFR therapy 🔗 Clonal fusions linked to MSI-H tumors 💡 Subclonal fusions may signal impending acquired resistance to targeted therapies like EGFR inhibitors offering a window for earlier intervention. Thanks to Andrew Pellatt for being a great co-fellow and letting me participate in this work along some of the defining leaders in CRC like @VanMorrisMD"  
[X Link](https://x.com/anyuser/status/1947852806607802592)  2025-07-23T02:54Z [----] followers, [----] engagements


"Another new paper out Grateful to have been a part of the effort. We (Andrew Pellatt and Arvind Dasari) asked: Can TAS-102 eliminate ctDNA-defined MRD in CRC after adjuvant chemo 💊 Single-arm phase II study of CRC pts with MRD by ctDNA after curative-intent therapy (Stage II to IV) 📉 ctDNA clearance in 47% at 3mo 36% at 6mo vs synthetic control: 7% clearance (P=.0034) 📈 Improved DFS (9.4 vs 5.75mo P=0.03) But clearance often transient not curative Proof of concept that MRD-guided escalation with TAS-102 can delay recurrence but more durable strategies are needed. 🔍 Results echo the ALTAIR"  
[X Link](https://x.com/anyuser/status/1947854862701445519)  2025-07-23T03:02Z [----] followers, [----] engagements


"CEA was discovered in [----]. By the 1970s CEACAM5 was recognized as a hallmark of colorectal cancer. Yet in [----] CRC still has no approved ADCs. That may change. 🚨 First-in-human data for Precem-TcT (anti-CEACAM5 + exatecan) now in Nature Medicine PROCEADE-CRC-01 dose escalation (N=40 irinotecan-refractory mCRC): 🧬 Efficacy: ORR: 7.5% confirmed (15% incl. unconfirmed) mPFS: [---] mo at DL [---] mg/kg 10% still on treatment at cutoff ⚠ Safety: DLTs: mainly hematologic at higher doses No ILD no ocular toxicity MTD: [---] mg/kg Q3W 📌 Takeaway: CEACAM5 has been an elusive target for decades."  
[X Link](https://x.com/anyuser/status/1950735039785832866)  2025-07-31T01:47Z [----] followers, [----] engagements


"Hot off the presses probably my favorite interventional paper of [----] (doesn't hurt that I look up to several of the authors as mentors or role models). 💉RAS vaccination is starting to look less like fantasy more like reality. Nature Medicine Wainberg et al 🎯 AMPLIFY-201 Phase [--] ELI-002 2P amphiphile vaccine n=25 (20 PDAC [--] CRC) median follow-up [----] mo Key results: T-cell threshold matters: 9.17-fold KRAS-specific T-cell expansion RFS HR [----] (p=0.0002) OS HR [----] (p=0.0099). PDAC subset: Median RFS [----] mo; OS [----] mo. For ctDNA+ PDAC MRD historical RFS/DFS [--] mo; OS [--] mo. Immunity: 100%"  
[X Link](https://x.com/anyuser/status/1956761870129389863)  2025-08-16T16:55Z [----] followers, 18.9K engagements


"Despite its rising incidence 📈 and poor outcomes we still have a limited understanding of the biology driving early-onset colorectal cancer (50y). Most prior studies were small inconsistent or confounded by MSI and treatment exposure. In JCO OA Futreal @skopetz and colleagues take a major step forward with an integrated proteotranscriptomic analysis 🧬 combining RNA sequencing and proteomic profiling across two independent MSS cohorts (MD Anderson + TCGA). This design allows for a clearer view of pathway activity and protein-level validation. Key findings: Wnt/-catenin signaling  EMT"  
[X Link](https://x.com/anyuser/status/1960890274537742483)  2025-08-28T02:20Z [----] followers, [----] engagements


"More @OncoAlert weekly RoundUp. This is the #1 method I use to keep up to date across tumor types (and @OncBrothers to be fair). monarchE with some expected data Immunotherapy marches on now in HR+ breast cancer Some GI studies to round things out (screening works and probably should be offered at a younger age). Thanks @weoncologists The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 22-28 [----] REGISTER at https://t.co/yzt83gqQkF OR https://t.co/dq8GEzl9ps Discussing: ✅News from Industry: monarchE Update 🦋 ✅Immunotherapy Boosts Pathological Response in HR+/HER2 Early"  
[X Link](https://x.com/anyuser/status/1961043233032536307)  2025-08-28T12:28Z [----] followers, [----] engagements


"Adjuvant therapy in colon cancer has come a long way. FOLFOX and capecitabine remain the backbone but a series of trials highlight how we can go beyond chemo as usual to improve both tolerability and efficacy: 🧬 ALASCCA In stage IIIII CRC with PI3K pathway mutations daily aspirin (160 mg) cut recurrence risk by 50% (HR 0.49). 🖐 D-TORCH Topical diclofenac gel reduced grade [--] hand-foot syndrome from 15% 3.8% at [--] weeks keeping more patients on full-dose capecitabine. 💊 B12 Methylcobalamin supplementation lowered the rate of clinically significant HFS (BMJ 2025) a low-cost and safe"  
[X Link](https://x.com/anyuser/status/1968880305730724067)  2025-09-19T03:30Z [----] followers, 16K engagements


"Every physician carries within himself a small cemetery where from time to time he goes to pray. Ren Leriche The guilt is real. Each name finds its place there quiet and heavy. What surprises me still are the families who meet loss with gratitudewho somehow thank you through their own heartbreak. That grace stays with you far longer than the failure ever does"  
[X Link](https://x.com/anyuser/status/1976490054303289382)  2025-10-10T03:28Z [----] followers, 70.7K engagements


"@ericpaulimd That is the original quote. Its also a bit longer and more brutal. Every surgeon carries within himself a small cemetery where from time to time he goes to pray a place of bitterness and regret where he must look for an explanation for his failures"  
[X Link](https://x.com/anyuser/status/1976811482169196644)  2025-10-11T00:45Z [----] followers, [----] engagements


"Biliary tract cancers are tough diseases; theyre rare mercurial (tissue can be a real challenge) and studies are challenging. Learned a lot working with Matt Gao as he put together this project on premature BTC trial discontinuation for #ASCOQLTY25 Congrats We are proud of @IowaMed MS3 Matthew Gao for representing the lab at #ASCOQLTY25 His work is focused on premature discontinuation of biliary tract cancer clinical trials @curecc Manuscript under review 📝 @TimothyJBrownMD @UGrewalMD @Deebacca @GIMedOnc https://t.co/N4hI1Tv9rL We are proud of @IowaMed MS3 Matthew Gao for representing the"  
[X Link](https://x.com/anyuser/status/1977011718632116265)  2025-10-11T14:01Z [----] followers, [----] engagements


"Unresectable intrahepatic cholangiocarcinoma (iCCA) remains brutal. Gem/Cis alone 3% 3-year OS. 💥 PUMP-2 (JCO 2025) adds HAIP FUDR + Gem/Cis 📈 Median OS [----] mo 💪 1-yr OS 80% 🔥 3-yr OS 31.5% Not randomized but striking signal. Pump trials arent easy; select patients equipoise challenges complex logistics. But for liver-confined disease regional therapy is an essential tool. I helped launch the @NorthwellHealth Manhattan HAI program to deliver this safely and selectively results like these remind us why. @TheGutOncLab @OncoAlert https://ascopubs.org/doi/10.1200/JCO-25-00923"  
[X Link](https://x.com/anyuser/status/1978313162433687631)  2025-10-15T04:13Z [----] followers, [----] engagements


"Holy smokes MATTERHORN hits OS 🏔🔥 Weve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma everyone wondered if adding immunotherapy could move the bar. Earlier this year MATTERHORN showed a big EFS win for DFLOT along with higher pCR and MPR rates but the question was would OS follow (and yes maybe I was doubting this) Now we have the answer: 🧬 OS HR [----] (95% CI 0.630.96 p=0.021) A clean statistically significant win. 💪 Benefit seen across PD-L1 subgroups (TAP 1% HR 0.79; TAP 1% HR 0.79). 🧫 More nodal downstaging: ypN 58% vs 45% OR 1.72"  
[X Link](https://x.com/anyuser/status/1978972825613414894)  2025-10-16T23:54Z [----] followers, 29.7K engagements


"#ESMO25 #UpperGI MATTERHORN confirms what the abstract hinted. ✅Positive study for OS BUT 🔹 In PD-L1 TAP 1% (HR 0.79; 95% CI 0.411.50) ➡ No clear benefit observed Consistent with prior metastatic dataPD-L1 negative patients remain unlikely to derive meaningful clinical benefit from IO in this setting. The biology just isnt there. @OncoAlert Holy smokes MATTERHORN hits OS 🏔🔥 Weve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma everyone wondered if adding immunotherapy could move the bar. Earlier this year MATTERHORN showed a big EFS win"  
[X Link](https://x.com/anyuser/status/1979166108205879558)  2025-10-17T12:42Z [----] followers, 19.8K engagements


"PREOPANC-2 drops and its a draw 🤜🤛 #ESMO25 Phase [--] trial out of the Netherlands comparing neoadjuvant FOLFIRINOX vs gemcitabine-based chemoradiotherapy (Gem-CRT) for resectable and borderline resectable pancreatic cancer. 🎯 Median OS: [----] mo (FOLFIRINOX) vs [----] mo (Gem-CRT) 🧮 HR [----] (95% CI 0.691.13 p=0.32) no significant difference 💀 Grade [--] AEs: 67% vs 60% 💧 Diarrhea notably higher with FOLFIRINOX (23% vs 1%) Takeaway: Both regimens deliver similar survival though toxicity and logistics differ. FOLFIRINOX didnt pull ahead here so the door stays open for gemcitabine-based CRT"  
[X Link](https://x.com/anyuser/status/1979167412902580531)  2025-10-17T12:47Z [----] followers, [----] engagements


"LEAP-014 takes the leap and lands flat 🪂 Updated results from LEAP-014 presented by Dr Jong-Su Sun testing chemo-IO lenvatinib in the first-line metastatic ESCC setting. 🧬 Primary endpoint OS not met [----] vs [----] months (p = 0.185) 💤 No benefit across key subgroups 📉 And the companion LEAP-015 in adenocarcinoma Also negative Takeaway: Despite a promising rationale adding lenvatinib to chemo-IO didnt move the needle. Effective second-line options remain limited and this space continues to represent a major unmet need. @OncoAlert @TheGutOncLab #ESMO25"  
[X Link](https://x.com/anyuser/status/1979250800464363727)  2025-10-17T18:18Z [----] followers, [----] engagements


"Tarlatamab keeps the fire alive in SCLC 🔥 Early data from this phase Ib study combining tarlatamab (DLL3-targeted BiTE) with 1L chemo-immunotherapy (platinum-etoposide + antiPD-L1) in extensive-stage SCLC show promising signals. 🧬 ORR 71% median DOR [--] mo Median PFS [---] mo 12-mo OS 81% notable in this disease ⚠ CRS in 56% (mostly grade 12) ICANS 6% overall (1% grade 3) 💉 Grade [--] TRAEs in 75% mainly cytopenias early on Takeaway: Manageable toxicity encouraging early survival and for a setting where durable benefit is rare thats worth attention. Very early given OS curves haven't separated"  
[X Link](https://x.com/anyuser/status/1979623850917658948)  2025-10-18T19:01Z [----] followers, [----] engagements


"CARES-009 raises the bar for resectable HCC 🧬🩸 Phase [--] CARES-009 trial tested perioperative camrelizumab (PD-1) + rivoceranib (VEGFR + PD-1 combo) vs upfront surgery in resectable intermediate/high-risk HCC (CNLC IbIIIa). 🧠 Design: [--] cycles neoadjuvant resection [--] cycles adjuvant IO/TKI 📈 EFS: [----] mo vs [----] mo (HR [----] 95% CI 0.410.85 p=0.004) 🧫 MPR: 35% (pCR 3%) vs 8% with surgery alone (p 0.001) 💥 BIRC-confirmed benefit (HR 0.63) OS immature (39 events) ⚠ Grade [--] TRAEs: 38% no unexpected safety signals Takeaway: The neoadjuvant era for HCC has arrived. @OncoAlert @TheGutOncLab"  
[X Link](https://x.com/anyuser/status/1979889481554767903)  2025-10-19T12:36Z [----] followers, [----] engagements


"NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer FOxTROT already showed us chemo doesnt work and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab  99% pathologic response 67% pathologic CR Zero recurrences to date at [--] years 🪦 This is the final coffin nail for perioperative chemotherapy in this setting. ATOMIC is already on life support despite being published less than a year ago. The real question now: with Cerceks rectal data can we safely omit surgery next At minimum this should be the new standard. At"  
[X Link](https://x.com/anyuser/status/1980031033618681888)  2025-10-19T21:59Z [----] followers, 28.3K engagements


"STELLAR-303 lights up the refractory CRC space 🌌🧬 @OncoAlert For the first time an IO-based regimen shows an OS benefit in microsatellite-stable (MSS) metastatic CRC a setting long resistant to immunotherapy. STELLAR-303 compared zanzalintinib + atezolizumab vs regorafenib in previously treated MSS mCRC. 📈 Median OS: [----] vs [---] mo HR [----] (95% CI 0.690.93 p=0.0045) 🧠 No-liver-met subset: [----] vs [----] mo (HR [----] p=0.087 interim) 💊 Grade [--] TRAEs: 60% vs 37% (5 treatment-related deaths) 🧩 Mechanistically: VEGFR/MET/AXL inhibition + PD-L1 blockade = chemo-free immune reactivation in cold"  
[X Link](https://x.com/anyuser/status/1980236433710363092)  2025-10-20T11:35Z [----] followers, [----] engagements


"Holy smokes. Amazed to be in the company of @ArndtVogel and @Erman_Akkus Looking forward to keep shining a critical eye towards #GIOnc. Really excited with all the progress that is being made. Thanks @Larvol @myESMO [----] Recap: Top GI Cancer Trials and Key Results Explore more insights and data from #ESMO25: https://t.co/6VyXEIDUr8 #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 #GICancer @Erman_Akkus @ArndtVogel https://t.co/Y3aPAccXE5 @myESMO [----] Recap: Top GI Cancer Trials and Key Results Explore more insights and data from"  
[X Link](https://x.com/anyuser/status/1981121055222841618)  2025-10-22T22:10Z [----] followers, [----] engagements


"Big day for a rare disease 🎉🧬 The new NCCN Guidelines for Appendiceal Cancer just dropped and theyre fantastic. For the first time this rare and often misunderstood disease finally gets its own dedicated guidance instead of the old just follow colorectal cancer footnote. 📘 Clear frameworks for diagnosis staging and management 🔍 Recognition that appendiceal primaries are biologically distinct 💡 Emphasis on multidisciplinary care and the need for more trials Only downside @jpshen_md and Michael Foote two of the biggest names in this space werent listed as contributors. Still a huge step"  
[X Link](https://x.com/anyuser/status/1985701842878070971)  2025-11-04T13:33Z [----] followers, 10.8K engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing